The body's own repair signal
A 43-residue peptide involved in actin dynamics, angiogenesis, and tissue repair.
Educational content. This page describes Thymosin Beta-4 for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Enhances fracture healing and myoblast recruitment, improving recovery from bone and muscle injuries.[6]
Thymosin beta-4 is a naturally occurring 43-amino acid peptide originally isolated from calf thymus tissue. It is the most abundant member of the beta-thymosin family, found in virtually all human tissues with particularly high concentrations in platelets, white blood cells, and wound fluid. Its primary intracellular function is sequestering G-actin monomers to regulate the dynamic equilibrium between monomeric and filamentous actin.
TB-500 is a synthetic fragment containing the active sequence Ac-LKKTETQ derived from thymosin beta-4, engineered for enhanced bioavailability. When tissues are injured, thymosin beta-4 acts as a powerful signaling molecule that recruits repair cells, promotes blood vessel growth, and modulates inflammation. Research interest expanded dramatically after the landmark 2007 Nature publication demonstrating cardiac progenitor cell activation.
At the molecular level, thymosin beta-4 regulates actin polymerization by binding G-actin monomers in a 1:1 complex, maintaining unpolymerized actin available for rapid filament assembly during cell migration. As little as 10 picograms can stimulate 2-3-fold increases in keratinocyte migration.
It exerts potent anti-inflammatory effects by inhibiting NF-kappaB signaling, blocking TNF-alpha-induced phosphorylation of IkappaB kinase through PINCH-1 and ILK interactions, suppressing IL-8 and IL-6 production.
Thymosin beta-4 drives angiogenesis by upregulating VEGF through HIF-1-alpha, and in cardiac tissue specifically activates dormant epicardial progenitor cells to differentiate into new cardiovascular cell types.
The body's own repair signal
Thymosin beta-4 sequesters G-actin to regulate cell migration; inhibits NF-kappaB-mediated inflammation; upregulates VEGF via HIF-1-alpha for angiogenesis; activates epicardial progenitor cells for cardiac regeneration; and attracts myoblasts and endothelial cells, orchestrating tissue repair while minimizing scarring.
Key studies supporting the therapeutic use of this peptide.
Safe and well-tolerated at doses up to 25 mcg/kg IV. Only mild-to-moderate adverse events, no dose-limiting toxicities.
Wang X, Liu L, Qi L, et al. — J Cell Mol Med, 25(17):8222-8228 (2021) · PubMed
Significantly accelerated corneal epithelial healing while reducing inflammatory markers.
Sosne G, Szliter EA, Barrett R, et al. — Exp Eye Res, 74(2):293-9 (2002) · PubMed
Activated epicardial progenitor cells, induced neovascularization, promoted new cardiomyocyte formation.
Smart N, Risebro CA, Melville AAD, et al. — Nature, 445(7124):177-82 (2007) · PubMed
Enhanced healing at 10-14 days with increased callus vascularity and bone formation.
Brady RD, Grills BL, Schuijers JA, et al. — J Orthop Res, 32(10):1277-82 (2014) · PubMed
Typical protocols used in clinical practice. Always consult a licensed provider for personalized dosing.
Subcutaneous Injection
Subcutaneous Injection: Loading phase first 4-6 weeks, then maintenance
Loading phase (first 4-6 weeks): Twice-weekly injections to achieve therapeutic tissue levels, then once-weekly maintenance.
Clinical improvement typically apparent within 2-4 weeks; significant tissue remodeling may require 6-12 weeks.
No formally established human dosing; based on preclinical research and early clinical data.
Phase 1 first-in-human study found no serious adverse events across a wide dose range. Preclinical toxicology identified no adverse effects at or above 60 mg/kg/day for 28 days IV.
Substantial gaps remain in long-term human safety data. Studies limited to Phase 1-2 with observation periods of 28-90 days.
As a peptide promoting cell growth and angiogenesis, theoretical risk exists in context of active malignancy.
See how Thymosin Beta-4 compares to peptides with overlapping benefits.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| Thymosin Beta-4 | Recovery & Healing | Injection | 6–12 weeks | Only peptide demonstrated to activate dormant cardiac progenitor cells for heart tissue regeneration |
| GHK-Cu | Anti-Aging & Recovery | Topical, Injection | 8–12 weeks | Only peptide demonstrated to modulate ~31% of human genes, epigenetically resetting cellular function toward a younger phenotype |
| BPC-157 | Recovery & Healing | Injection, Oral | 4–8 weeks | Uniquely stable in gastric acid; broad multi-system healing with human IBD trial data |
| CJC-1295 | Anti-Aging & Recovery | Injection (weekly or daily) | 8–12 weeks | Only GHRH analog with covalent albumin-binding mechanism extending half-life to 6-8 days, allowing once-weekly dosing |
| KPV | Anti-Inflammatory & Wound Healing | Injection, Oral, Topical | 4 to 8 weeks | Smallest known anti-inflammatory peptide that directly blocks NF-kB nuclear import without melanocortin receptor binding, cAMP elevation, or pigmentation effects |
Current FDA classification and compounding eligibility.
The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
In April 2026, HHS Secretary Robert F. Kennedy Jr. announced that nominators withdrew 12 peptides from Category 2 of the FDA's 503A bulk drug substances evaluation, including this one. The FDA referred them to its Pharmacy Compounding Advisory Committee (PCAC) for re-evaluation at meetings beginning July 2026. If PCAC recommends Category 1 status and the FDA agrees, licensed 503A pharmacies could compound it under FDA enforcement discretion again. The outcome is not final.
Listed in Category 2 as 'Thymosin Beta-4, Fragment (LKKTETQ)', the form commonly marketed as TB-500. FDA flagged angiogenesis mechanism as a potential tumor-growth concern. Not eligible for compounding under the interim policy.
Listed as 'Thymosin Beta-4, Fragment (LKKTETQ)' in 503A Category 2
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Looking into Thymosin Beta-4? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA tripeptide-copper complex that supports skin regeneration and wound healing.
Naturally occurring in plasma; levels decline with age. Widely used in topical and compounded formulations.
A 15-residue peptide derived from gastric juice, used for tissue and gut repair.
Most studied for tendon, ligament, and GI recovery; controlled human data remains limited.
A stabilized GHRH analog designed to extend the half-life of natural growth hormone pulses.
Widely compounded before 2023; currently flagged by FDA for aggregation and immunogenicity concerns.